Sonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn® (hypochlorous acid) for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars
PETALUMA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced receipt of two new regulatory approvals from the Singapore government for its Microcyn® Technology-based hydrogels.
The first approval is for EZyma™ Hydrogel, which is intended for the management of itching dryness, redness, burning and pain associated with atopic dermatitis. The second clearance is for ScarLess™ Hydrogel to be used as an adjuvant in the wound healing process as well for managing and reducing new and existing hypertrophic and keloid scars.
“We have seen these dermatological hydrogels successfully address both atopic dermatitis and management of scars around the globe,” said Bruce Thornton, Sonoma Pharmaceuticals vice president of international sales. “So we are most pleased to be able to bring these innovative technologies to dermatologists and plastic surgeons in Singapore and Malaysia, thus enabling these healthcare professionals to further improve patient outcomes.”
Sonoma’s distribution partner in Singapore, Dyamed Biotech, will launch both products in September 2017.
Theodore Tan, managing director and co-founder of Dyamed, said, “For over 12 years our strong and close partnership has continued to grow with Sonoma Phrmaceuticals and we are very excited to introduce the next line of Microcyn-based products for dermatology use in Singapore and Malaysia with EZyma and ScarLess.”
About Atopic Dermatitis
In a 2015 study published in the Annals of Nutrition & Metabolism, atopic dermatitis is shown to be a chronic inflammatory skin disease posing a significant burden on health-care resources and patients' quality of life. A complex disease with a wide spectrum of clinical presentations and combinations of symptoms, atopic dermatitis affects up to 20% of children and up to 3% of adults; recent data show that its prevalence is still increasing, especially in low-income countries.
Scar Treatment Market
According to a P&S Market Research report, the global scar treatment market accounted for $15,944 billion in revenue in 2015, and it is expected to grow at a CAGR of 10.0% during 2016-2022. The topical treatment segment dominated the global market in 2015 with about 60.9% share. The global scar treatment market is witnessing high growth rate, due to growing cases with skin problems leading to scar formation, availability of technologically advanced products, which have the capability to fade away the scars and increasing appearance consciousness among consumers. Also, the increasing expenditure on personal care is further propelling the growth of the market.
About Sonoma Pharmaceuticals, Inc.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals® and Microcyn® Technology are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact: Sonoma Pharmaceuticals, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105 dmcfadden@Sonomais.com
Released June 20, 2017